Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis
Objectives The response to glucagon-like peptide-1 (GLP-1) analogues for weight loss varies significantly. We investigated the anthropometric, demographic and clinical characteristics associated with total body weight loss (TBWL) from subcutaneous GLP-1 analogue therapy in patients with obesity in a real-world setting. Design Retrospective cohort analysis. Setting An urban, multidisciplinary obesity community clinic in Vancouver, Canada, from November 2018 to April 2021. Participants 483 adults with a body mass index (BMI) of ≧30 kg/m2 who had filled a new prescription for subcutaneous semaglutide or liraglutide, with at least 6-month follow-up, were included (mean follow-up: 17.3 months). Individuals with prior bariatric surgery were excluded. Outcomes The primary outcome was the %TBWL over a mean follow-up period of 520 days. Participant’s TWBL was categorised as non-response (15% TBWL). Results The average %TBWL in the c
